A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

January 19, 2028

Study Completion Date

January 21, 2028

Conditions
Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Non-HodgkinMyelodysplastic SyndromesNeoplasmsSolid Tumor, AdultMetastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions
DRUG

JNJ-75348780

Participants from the parent study (75348780LYM1001 \[NCT04540796\]) who are deriving benefit from study treatment will continue to receive subcutaneous JNJ-75348780.

DRUG

JNJ-67856633

Participants from the parent studies (64264681LYM1002 \[NCT04657224\], 67856633LYM1002 \[NCT04876092\] and 67856633LYM1001 \[NCT03900598\]) who are deriving benefit from study treatment will continue to receive JNJ-67856633 orally.

DRUG

JNJ-54179060

Participants from the parent study (67856633LYM1002 \[NCT04876092\]) who are deriving benefit from study treatment will continue to receive JNJ-54179060 orally.

DRUG

JNJ-64264681

Participants from the parent studies (64264681LYM1001 \[NCT04210219\], 64264681LYM1002 \[NCT04657224\]) who are deriving benefit from study treatment will continue to receive JNJ-64264681 orally.

DRUG

JNJ-74856665

Participants from the parent study (74856665AML1001 \[NCT04609826\]) who are deriving benefit from study treatment will continue to receive JNJ-74856665 orally.

DRUG

JNJ-70218902

Participants from the parent study (70218902EDI1001 \[NCT04397276\]) who are deriving benefit from study treatment will continue to receive JNJ-70218902 orally.

DRUG

JNJ-64619178

Participants from the parent study (64619178EDI1001 \[NCT03573310\]) who are deriving benefit from study treatment will continue to receive JNJ-64619178 orally.

Trial Locations (26)

100

National Taiwan University Hospital, Taipei

704

National Cheng Kung University Hospital, Tainan City

833

Chang Kung Memorial Hospital, Kaohsiung City

2025

Arensia Exploratory Medicine, Chisinau

9000

Ghent University Hospital, Ghent

28040

Hosp Univ Fund Jimenez Diaz, Madrid

31008

Clinica Univ. de Navarra, Pamplona

44093

CHU Nantes, Nantes

59000

Hopital Claude Huriez, Lille

94805

Institut Gustave Roussy, Villejuif

404327

China Medical University Hospital, Taichung

3109601

Rambam Medical Center, Haifa

9112001

Hadassah University Hospita Ein Kerem, Jerusalem

Postal code 0112

Arensia Exploratory Medicine, Tbilisi

115 28

Alexandra Hospital, Athens

460-0001

National Hospital Organization Nagoya Medical Center, Nagoya

135 8550

The Cancer Institute Hospital of JFCR, Tokyo

80 214

Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz, Gdansk

30-727

Pratia MCM Krakow, Krakow

60-185

Aidport Sp z o o, Skorzewo

03722

Severance Hospital Yonsei University Health System, Seoul

08035

Hosp Univ Vall D Hebron, Barcelona

01135

Medical Center of Limited Liability Company Arensia Exploratory Medicine, Kyiv

Le1 5ww

University Hospitals Of Leicester Nhs Trust, Leicester

EC1A 7BE

St Bartholomews Hospital, London

PL6 8DH

University Hospitals Plymouth NHS Trust, Plymouth

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT06788509 - A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring | Biotech Hunter | Biotech Hunter